Shimon Slavin, MD, Founder of Israel’s National Stem Cells Transplantation Center at Hadassah Medical Center in Jerusalem, is currently the Director of Biotherapy International in Tel Aviv, The Center for Cancer Immunotherapy & Cellular Medicine, also serving as Medical director HepC Therapeutics in Partnership with ProBioGen AG, Berlin. Slavin pioneered the use of personalized anti-cancer immunotherapy mediated by donor lymphocyte infusion (DLI) following allogeneic stem cell transplantation, later developing the use of alloreactive donor lymphocytes targeted by monoclonal antibodies for treatment of cancer. Slavin introduced clinical application of non-myeloablative, reduced intensity conditioning, for safer stem cell transplantation for cure of malignant and life-threatening non-malignant disorders, including treatment of autoimmune diseases and induction of transplantation tolerance to bone marrow and organ allografts based on selective depletion of alloreactive T cells for prevention of rejection and graft-vs-host disease. Slavin introduced the clinical application of monoclonal anti-CD52 antibody, now approved by FDA as Lemtrada (Alemtuzumab) for treatment of multiple sclerosis and CLL. Being involved in cellular medicine, Slavin accomplished the first successful gene therapy for treatment of severe combined immune deficiency and pioneered new procedures for using multi-potent mesenchymal stromal cells for multi-system regenerative medicine. Slavin authors 4 books, 669 scientific publications, serving on many editorial boards and received many international awards in recognition for his contributions for treatment of cancer.